Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Journal of Biopharmaceutical Statistics
|
June 5, 2026
Pivotal trial design considerations for new and next generation cell and gene therapies
Patricia Anderson, Zhenzhen Xu, Evgeny Degtyarev, et al.
Journal of Comparative Effectiveness Research
|
June 22, 2023
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma
Yanni Hao, Wei-Chun Hsu, Craig S Parzynski, et al.
Therapeutic Innovation & Regulatory Science
|
February 5, 2024
Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework
Rima Izem, Emmanuel Zuber, Nadia Daizadeh, et al.
Journal of Patient-Reported Outcomes
|
August 25, 2020
What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
Rachael Lawrance, Evgeny Degtyarev, Philip Griffiths, et al.
JCO Precision Oncology
|
February 1, 2022
Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials
Evgeny Degtyarev, Yiyun Zhang, Kapildeb Sen, et al.
Blood Advances
|
January 14, 2022
Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
Richard T Maziarz, Jie Zhang, Hongbo Yang, et al.
Statistics in Biopharmaceutical Research
|
June 30, 2021
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework
Evgeny Degtyarev, Kaspar Rufibach, Yue Shentu, et al.
Pharmaceutical Statistics
|
November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting
Michelle Casey, Evgeny Degtyarev, María José Lechuga, et al.
Future Oncology (London, England)
|
June 18, 2024
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Evgeny Degtyarev, Natacha Bolaños, Joshua D Brody, et al.
Pharmaceutical Statistics
|
October 4, 2021
Estimands for overall survival in clinical trials with treatment switching in oncology
Juliane Manitz, Natalia Kan-Dobrosky, Hannes Buchner, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Journal of Biopharmaceutical Statistics
|
June 5, 2026
Pivotal trial design considerations for new and next generation cell and gene therapies
Patricia Anderson, Zhenzhen Xu, Evgeny Degtyarev, et al.
Journal of Comparative Effectiveness Research
|
June 22, 2023
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma
Yanni Hao, Wei-Chun Hsu, Craig S Parzynski, et al.
Therapeutic Innovation & Regulatory Science
|
February 5, 2024
Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework
Rima Izem, Emmanuel Zuber, Nadia Daizadeh, et al.
Journal of Patient-Reported Outcomes
|
August 25, 2020
What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
Rachael Lawrance, Evgeny Degtyarev, Philip Griffiths, et al.
JCO Precision Oncology
|
February 1, 2022
Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials
Evgeny Degtyarev, Yiyun Zhang, Kapildeb Sen, et al.
Blood Advances
|
January 14, 2022
Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
Richard T Maziarz, Jie Zhang, Hongbo Yang, et al.
Statistics in Biopharmaceutical Research
|
June 30, 2021
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand Framework
Evgeny Degtyarev, Kaspar Rufibach, Yue Shentu, et al.
Pharmaceutical Statistics
|
November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting
Michelle Casey, Evgeny Degtyarev, María José Lechuga, et al.
Future Oncology (London, England)
|
June 18, 2024
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Evgeny Degtyarev, Natacha Bolaños, Joshua D Brody, et al.
Pharmaceutical Statistics
|
October 4, 2021
Estimands for overall survival in clinical trials with treatment switching in oncology
Juliane Manitz, Natalia Kan-Dobrosky, Hannes Buchner, et al.
Page
of 2